Today's News: VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 8, 2011) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH - News; OTCQB:APCSF) (the "Company" or "ALDA") announces that Natural Product Number ("NPN") 80026033 has been issued for a 0.5% hydrocortisone (0.5% HC) ointment. The Company is authorized to sell this product in Canada for temporary relief of minor skin irritations, rashes, itching and redness due to eczema, insect bites, poison ivy and other irritating plants; contact dermatitis caused by soaps, detergents, cosmetics, jewellery and other materials that irritate the skin; seborrheic dermatitis and psoriasis.
Typically, skin conditions of these types (which affect over 75% of Canadian adults at one time or another) begin as an inflammatory condition, but are often worsened or prolonged by secondary infection with bacteria or fungi (such as the fungi that causes athlete's foot). The combination of an effective anti-microbial product (such as the T36® formulation) with an anti-inflammatory agent (such as 0.5% hydrocortisone) would address this common medical condition more effectively and make treatment recommendations more straightforward for the health care provider and much easier to carry out for the patient. This innovative combination of an anti-microbial and anti-inflammatory therapy (avoiding the need to apply separate products to treat a single condition) represents an important step forward in the non-prescription therapeutic market. It is also consistent with the current approach favoured by a number of health providers encouraging Canadians to take charge in a positive way of their own care. Obtaining registration of a hydrocortisone ointment is a first step for the Company in bringing this approach to market.
